STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma

NACompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

October 24, 2017

Primary Completion Date

June 28, 2019

Study Completion Date

February 28, 2020

Conditions
Localized Hepatocellular Carcinoma
Interventions
DEVICE

Tandem Microsphere loaded with Epirubicin

The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)

Trial Locations (10)

Unknown

Beijing Cancer Hospital, Beijing

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Guangdong Nanfang Hospital, Guangzhou

Henan Cancer Hospital, Zhengzhou

Zhongda Hospital Affiliated Southeast University, Nanjing

Shengjing Hospital Affiliated China Medical University, Shenyang

Shanghai Zhongshan Hospital, Shanghai

Second Aff. Hosp. of Zhejiang University College of Medicine, Hangzhou

The First Affiliated Hospital, Zhejiang University, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

Sponsors
All Listed Sponsors
lead

Varian Medical Systems

INDUSTRY

NCT03113955 - STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter